Terms: = Lymphoma AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
27 results:
1. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic lymphoma Kinase Inhibitor.
Gupta N; Hanley MJ; Griffin RJ; Zhang P; Venkatakrishnan K; Sinha V
Clin Pharmacokinet; 2023 Aug; 62(8):1063-1079. PubMed ID: 37493887
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Jacobs SS; Dome JS; Gai J; Gross AM; Postell E; Hinds PS; Davenport L; van den Anker JN; Mowbray C
Support Care Cancer; 2022 Apr; 30(4):3513-3520. PubMed ID: 35018520
[TBL] [Abstract] [Full Text] [Related]
3. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract] [Full Text] [Related]
4. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor.
Rioux N; Duncan KW; Lantz RJ; Miao X; Chan-Penebre E; Moyer MP; Munchhof MJ; Copeland RA; Chesworth R; Waters NJ
Xenobiotica; 2016; 46(3):268-77. PubMed ID: 26294260
[TBL] [Abstract] [Full Text] [Related]
5. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.
Kim IW; Han N; Kim MG; Kim T; Oh JM
Pharmacogenet Genomics; 2015 Jan; 25(1):1-7. PubMed ID: 25379720
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Altés A; Paré L; Esquirol A; Xicoy B; Rámila E; Vicente L; López R; Orriols J; Vall-llovera F; Sánchez-González B; del Río E; Sureda A; Páez D; Baiget M
Leuk Lymphoma; 2013 Aug; 54(8):1706-12. PubMed ID: 23323945
[TBL] [Abstract] [Full Text] [Related]
7. Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Fredenhagen A; Kittelmann M; Oberer L; Kuhn A; Kühnöl J; Délémonté T; Aichholz R; Wang P; Atadja P; Shultz MD
Drug Metab Dispos; 2012 May; 40(5):1041-50. PubMed ID: 22344701
[TBL] [Abstract] [Full Text] [Related]
8. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, cyp2d6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians.
Gra O; Mityaeva O; Berdichevets I; Kozhekbaeva Z; Fesenko D; Kurbatova O; Goldenkova-Pavlova I; Nasedkina T
Genet Test Mol Biomarkers; 2010 Jun; 14(3):329-42. PubMed ID: 20373852
[TBL] [Abstract] [Full Text] [Related]
9. Role of the cyp2d6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.
Silveira Vda S; Canalle R; Scrideli CA; Queiroz RG; Tone LG
Environ Mol Mutagen; 2010 Jan; 51(1):48-56. PubMed ID: 19593802
[TBL] [Abstract] [Full Text] [Related]
10. Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.
da Silva Silveira V; Canalle R; Scrideli CA; Queiroz RG; Bettiol H; Valera ET; Tone LG
Leuk Res; 2009 Jul; 33(7):898-901. PubMed ID: 19162321
[TBL] [Abstract] [Full Text] [Related]
11. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract] [Full Text] [Related]
12. Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.
Gra OA; Glotov AS; Nikitin EA; Glotov OS; Kuznetsova VE; Chudinov AV; Sudarikov AB; Nasedkina TV
Am J Hematol; 2008 Apr; 83(4):279-87. PubMed ID: 18061941
[TBL] [Abstract] [Full Text] [Related]
13. Study of genetic polymorphism of xenobiotic enzymes in acute leukemia.
Eyada TK; El Ghonemy EG; El Ghoroury EA; El Bassyouni SO; El Masry MK
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):489-95. PubMed ID: 17581325
[TBL] [Abstract] [Full Text] [Related]
14. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms.
van der Padt A; van Schaik RH; Sonneveld P
Neth J Med; 2006 May; 64(5):160-2. PubMed ID: 16702617
[TBL] [Abstract] [Full Text] [Related]
15. Role of cyp2d6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.
Aydin-Sayitoglu M; Hatirnaz O; Erensoy N; Ozbek U
Am J Hematol; 2006 Mar; 81(3):162-70. PubMed ID: 16493615
[TBL] [Abstract] [Full Text] [Related]
16. Genetic polymorphism of CYP1A1, cyp2d6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children.
Joseph T; Kusumakumary P; Chacko P; Abraham A; Radhakrishna Pillai M
Pediatr Blood Cancer; 2004 Oct; 43(5):560-7. PubMed ID: 15382273
[TBL] [Abstract] [Full Text] [Related]
17. Cytochrome P450 gene polymorphism and cancer.
Agundez JA
Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of pharmacokinetics, pharmacodynamics, and pharmacogenomics data sets using VizStruct, a novel multidimensional visualization technique.
Bhasi K; Zhang L; Zhang A; Ramanathan M
Pharm Res; 2004 May; 21(5):777-80. PubMed ID: 15180333
[TBL] [Abstract] [Full Text] [Related]
19. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.
Krajinovic M; Labuda D; Mathonnet G; Labuda M; Moghrabi A; Champagne J; Sinnett D
Clin Cancer Res; 2002 Mar; 8(3):802-10. PubMed ID: 11895912
[TBL] [Abstract] [Full Text] [Related]
20. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
Roddam PL; Rollinson S; Kane E; Roman E; Moorman A; Cartwright R; Morgan GJ
Pharmacogenetics; 2000 Oct; 10(7):605-15. PubMed ID: 11037802
[TBL] [Abstract] [Full Text] [Related]
[Next]
